Licensed by Pfizer Catalog No.S1835 Synonyms: CP-62993, XZ-450
Molecular Weight(MW): 748.98
Azithromycin is an antibiotic by inhibiting protein synthesis, used for the treatment of bacterial infections.
Purity & Quality Control
Choose Selective Autophagy Inhibitors
|Description||Azithromycin is an antibiotic by inhibiting protein synthesis, used for the treatment of bacterial infections.|
Azithromycin reduces about 40% of IL-8 mRNA and protein expression in cystic fibrosis (CF) cells reaching the levels of non-CF cells. Azithromycin results in 50% and 70% reduction of NF-kappaB and AP-1 DNA binding, respectively, leading to levels of non-CF cells.  Azithromycin significantly enhances the intensity of a co-stimulatory molecule, CD80, on DCs but not CD86 and CD40 in dendritic cells (DCs). Azithromycin significantly increases the production of IL-10 and Clarithromycin (CAM) significantly inhibits the production of IL-6 by DCs. Azithromycin increases IL-10 and CAM decreases IL-2 productions significantly, when naive T cells derived from spleen are co-cultured with DCs treated in advance with LPS and these macrolides.  Azithromycin selectively inhibits fluid-phase endocytosis of horseradish peroxidase and lucifer yellow in J774 mouse macrophages. Azithromycin delays sequestration of receptor-bound transferrin and peroxidase-anti-peroxidase immune complexes into cell-surface endocytic pits and vesicles. Azithromycin down-regulates cell surface transferrin receptors, but not Fc gamma receptors, by causing a major delay in the accessibility of internalized transferrin receptors to the recycling route, without slowing down subsequent efflux, resulting in redistribution of the surface pool to an intracellular pool.  Azithromycin inserts into the DOPC lipid bilayer, so as to decrease its cohesion and to facilitate the merging of DPPC into the DOPC fluid matrix. 
|In vitro||DMSO||100 mg/mL (133.51 mM)|
|Ethanol||100 mg/mL (133.51 mM)|
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).
Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:
Concentration (start) x Volume (start) = Concentration (final) x Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )
* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).
Molecular Weight Calculator
Enter the chemical formula of a compound to calculate its molar mass and elemental composition:
Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2
Instructions to calculate molar mass (molecular weight) of a chemical compound:
To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.
Definitions of molecular mass, molecular weight, molar mass and molar weight:
Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.
Clinical Trial Information
|NCT Number||Recruitment||Conditions||Sponsor/Collaborators||Start Date||Phases|
|NCT02708992||Active, not recruiting||Gonorrhoea||National Institute of Allergy and Infectious Diseases (NIAID)||April 28, 2016||Phase 1|
|NCT02707042||Recruiting||Physiological Response to Antibiotics||National Institute of Allergy and Infectious Diseases (NIAID)|National Institutes of Health Clinical Center (CC)||February 26, 2016||Phase 1|
|NCT02972957||Not yet recruiting||Influenza||Medical Research Council Unit, The Gambia|University of Edinburgh|Public Health England|University of Oxford|National Institute for Public Health and the Environment (RIVM)||January 2017||Phase 4|
|NCT03032042||Not yet recruiting||Helminth Infection||Francis I. Proctor Foundation||January 2017||Phase 4|
|NCT02911935||Recruiting||Respiratory Syncytial Virus, Bronchiolitis||Washington University School of Medicine||November 2016||Phase 2|Phase 3|
|NCT02872298||Not yet recruiting||Asthma||Holaira||October 2016||Phase 1|
Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.